ROIV

In the past six months, Roivant Sciences Ltd. stock has trended upwards by 38.51% and has seen its share price increase by 31.6% since the beginning of the year. A $2.25 billion global settlement with Moderna significantly fortified its balance sheet. Positive Phase 2 efficacy data for brepocitinib and its FDA Priority Review were positive catalysts. Topline results from two Phase 3 studies of batoclimab in thyroid eye disease did not meet the primary endpoint. Bullish analyst coverage has driven investor enthusiasm. There have been reports of insider selling, while Vanguard raised its stake. Roivant reported Q3 2026 EPS of -$0.24, beating estimates, but revenue missed forecasts.